Buy · Sell · Fund · Build
One read. Four decisions.
Every decision in the Molecule Economy is a decision about a molecule. The same mechanistic read answers each one, before the money moves.
BuyCapital · Transact
Price what the seller hasn't.
For pharma BD, private equity, acquirers and advisory funds
- Before the term sheet
Pharma BD or M&A
The read showsThe value the seller hasn't priced, and the risk they haven't disclosed
- Before the bid
Private equity or an acquirer
The read showsWhether the lead indication holds, and the indications not yet priced
- Before signing
A licensee
The read showsThe indication priced on its mechanism, not the headline
- Before the rescue terms are set
An advisory fund in a rescue transaction
The read showsWhat the molecule can still do, on mechanism, not on distress
Read the molecule before you price it.
SellOwners · Transact
Your molecule is already being read.
For biotechs, licensors, cross-border sellers and advisory funds
- Before the round is priced
A biotech raising capital
The read showsWhere the molecule is strongest: indication, patients, partner
- Before the data room opens
A seller in a licensing or M&A process
The read showsThe indications and patients that set the price
- Before the first Western buyer meeting
A cross-border licensor
The read showsOne read both sides can rely on
- Before it is written down
An asset owner with a shelved molecule
The read showsWhere else the mechanism fits
- Before the asset is marked down
An advisory fund running a rescue sale
The read showsWhere the molecule still works, and in whom
One clock for everyone
- SealedNo one
Only its fingerprint is published. The read cannot be edited or withdrawn.
- Orders closeEvery buyer, and the owner
Released at the same moment, before the readout. The owner may publish a response alongside.
- After the readoutEveryone
Revealed free and scored on the Ledger.
Every one of these decisions will be made with a read. The only question is whose.
FundCapital · Develop
Back the program before the readout.
For VCs, hedge and sovereign funds, and payers
- Before the readout
A fund holding the stock
The read showsWhether the trial enrolls the patients who respond
- Before the round is priced
A venture investor
The read showsWhether the lead indication holds, and where else it fits
- Before the allocation
A sovereign or public fund
The read showsWhich programs the mechanism supports
- Before funding a trial or program
A payer or health sponsor
The read showsWhich patients are predicted to benefit, and why
Odds tell you how often. Mechanism tells you why.
BuildOwners · Develop
Simulate the Trial before you run it.
For pharma, biotech and sponsors
- Before the first patient
A pharma pipeline
The read showsWhether the primary indication holds, and where else it fits
- Before enrollment
A trial sponsor or CRO
The read showsThe patients who respond, and the partner drug that helps them
- Before the first patient
A rare-disease company
The read showsResponders and the responder biomarker, from a trial run first in their cells
Read the molecule before you build the trial.